HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mauro Salvi Selected Research

Mauro Salvi Research Topics

Disease

14Neoplasms (Cancer)
10/2021 - 12/2002
4Cystic Fibrosis (Mucoviscidosis)
03/2022 - 12/2018
3Synucleinopathies
10/2017 - 02/2012
3Parkinson Disease (Parkinson's Disease)
10/2017 - 02/2012
2COVID-19
10/2021 - 01/2021
2Neuroblastoma
01/2021 - 01/2014
1Cardiovascular Diseases (Cardiovascular Disease)
10/2021
1Infections
10/2021
1Osteosarcoma (Osteogenic Sarcoma)
01/2021
1Cholangiocarcinoma
10/2019
1Shock
12/2018
1Disease Progression
10/2017
1Multiple Sclerosis
10/2015
1Virus Diseases (Viral Diseases)
09/2009
1Liver Diseases (Liver Disease)
08/2007
1Reye Syndrome (Reye's Syndrome)
10/2005

Drug/Important Bio-Agent (IBA)

5Phosphotransferases (Kinase)IBA
12/2020 - 09/2009
4Protein Kinases (Protein Kinase)IBA
10/2021 - 01/2019
4Casein Kinase II (Casein Kinase 2)IBA
03/2021 - 01/2019
4Proteins (Proteins, Gene)FDA Link
01/2021 - 09/2009
3Pharmaceutical PreparationsIBA
10/2021 - 10/2015
3silmitasertibIBA
10/2021 - 12/2020
3SynucleinsIBA
10/2017 - 02/2012
2EnzymesIBA
01/2014 - 01/2006
2AntioxidantsIBA
01/2006 - 10/2005
1tezacaftorIBA
03/2022
1elexacaftorIBA
03/2022
1tezacaftor drug combination ivacaftor elexacaftorIBA
03/2022
1ivacaftorIBA
03/2022
1Protein Isoforms (Isoforms)IBA
01/2021
15- (3- ethynylphenylamino)pyrimido(4,5- c)quinoline- 8- carboxylic acidIBA
11/2020
12- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA
01/2020
1Phosphates (Orthophosphate)IBA
01/2017
1SphingosineIBA
10/2015
1Fingolimod Hydrochloride (FTY720)FDA Link
10/2015
1Phosphoric Monoester Hydrolases (Phosphatases)IBA
01/2014
1Peptide LibraryIBA
01/2014
1ProteomeIBA
01/2014
1DNA (Deoxyribonucleic Acid)IBA
09/2009
1PhosphopeptidesIBA
09/2009
1CatalaseIBA
08/2007
1Oxidoreductases (Dehydrogenase)IBA
01/2006
1Biogenic Amines (Biogenic Amine)IBA
01/2006
1AminesIBA
01/2006
1AldehydesIBA
01/2006
1Reactive Oxygen Species (Oxygen Radicals)IBA
01/2006
1GenisteinIBA
12/2002
1IsoflavonesIBA
12/2002

Therapy/Procedure

5Therapeutics
03/2022 - 12/2018